SkyePharma confirms appointments of Frank Condella and Ken Cunningham

13 February 2006

UK drug delivery specialist group SkyePharma has confirmed the appointment of Frank Condella as chief executive and Ken Cunningham as chief operating officer, with both signing contracts for one year. The company also rejected the call by shareholder activists to name Bob Thian as chairman, a post that has been given to Argeris Karabelas (see page 2) following the ousting of Ian Gowrie-Smith. It also said that Mr Thian had rejected the possibility of being elected a non-executive director.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight